IL6 and non-small cell lung carcinoma: Anti-IL-6 antibody treatment in late-stage cachexia has been unsuccessful in clinical trials involving participants with non-small-cell lung cancer, and the pleiotropic effects of IL-6 might lead to side effects such as an increased risk of infections.